168 related articles for article (PubMed ID: 20857708)
1. [A patient with cardiovascular risk factors and comorbidities: integration of indications and contra-indications in pharmacotherapy].
Scheen AJ
Rev Med Liege; 2010; 65(7-8):476-81. PubMed ID: 20857708
[TBL] [Abstract][Full Text] [Related]
2. [Drug selection guided by known and newly diagnosed comorbidities in a multi-risk patient].
Scheen AJ
Rev Med Liege; 2008 Nov; 63(11):693-6. PubMed ID: 19112997
[TBL] [Abstract][Full Text] [Related]
3. [When should we start the treatment of the cardiovascular risk factors].
de Berrazueta Fernández JR
An R Acad Nac Med (Madr); 2008; 125(1):125-36; discussion 136-44. PubMed ID: 18777847
[TBL] [Abstract][Full Text] [Related]
4. Drug treatment of metabolic syndrome.
Altabas V
Curr Clin Pharmacol; 2013 Aug; 8(3):224-31. PubMed ID: 22950955
[TBL] [Abstract][Full Text] [Related]
5. Introductory remarks.
Velasco M; Bermúdez V; Israili ZH; Hernández-Hernández R
Am J Ther; 2010; 17(3):236. PubMed ID: 20479578
[No Abstract] [Full Text] [Related]
6. Total risk factor management in patients with type 2 diabetes.
Betteridge J
Br J Hosp Med (Lond); 2005 Sep; 66(9):529-33. PubMed ID: 16200798
[No Abstract] [Full Text] [Related]
7. [Cardiometabolic high risk patients with abdominal obesity. Frequency and risk factor profile in primary care].
Scholze J; Lilienthal W; Bramlage P
MMW Fortschr Med; 2007 Sep; 149 Suppl 3():103-10. PubMed ID: 17955787
[TBL] [Abstract][Full Text] [Related]
8. A practical approach to reducing cardiovascular risk factors.
Fonarow GC
Rev Cardiovasc Med; 2007; 8 Suppl 4():S25-36. PubMed ID: 17934391
[TBL] [Abstract][Full Text] [Related]
9. ESH-ESC guidelines for the management of hypertension.
Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
[TBL] [Abstract][Full Text] [Related]
10. [Cardiovascular prevention in diabetes mellitus: A multifactorial challenge].
Pedro-Botet J; Chillarón JJ; Benaiges D; Flores-Le Roux JA
Clin Investig Arterioscler; 2016; 28(3):154-63. PubMed ID: 26655375
[TBL] [Abstract][Full Text] [Related]
11. Solvay addresses unmet needs in the management of hypertensive patients with cardiometabolic and lipid disorders.
Cardiovasc J Afr; 2009; 20(1):73-4. PubMed ID: 19287821
[No Abstract] [Full Text] [Related]
12. Clinical implications of the metabolic syndrome.
Ceska R
Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S2-4. PubMed ID: 17935057
[TBL] [Abstract][Full Text] [Related]
13. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.
Mazzone T
Am J Med; 2007 Sep; 120(9 Suppl 2):S26-32. PubMed ID: 17826043
[TBL] [Abstract][Full Text] [Related]
14. The significance of plasma adrenomedullin and calcitonin gene-related peptide concentration in patients with Type 2 diabetes mellitus who are treated for cardiovascular risk factors.
Charvat J; Svab P; Havlin J; Bilek R; Zamrazil V
Neuro Endocrinol Lett; 2014; 35(2):154-8. PubMed ID: 24878981
[TBL] [Abstract][Full Text] [Related]
15. Application of the SCORE and Wilson-Grundy methods for the assessment of cardiovascular risk in community pharmacies.
Amariles P; Machuca M; Faus MJ; Baena MI; Martinez-Martinez F; Jimenez-Martin J
J Clin Pharm Ther; 2008 Oct; 33(5):475-81. PubMed ID: 18834361
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the assessment and management of cardiometabolic risk in patients with and without type 2 diabetes mellitus in Canadian primary care.
Teoh H; Després JP; Dufour R; Fitchett DH; Goldin L; Goodman SG; Harris SB; Langer A; Lau DC; Lonn EM; Mancini GB; McFarlane PA; Poirier P; Rabasa-Lhoret R; Tan MK; Leiter LA
Diabetes Obes Metab; 2013 Dec; 15(12):1093-100. PubMed ID: 23683111
[TBL] [Abstract][Full Text] [Related]
17. The current unmet need in type 2 diabetes mellitus: addressing glycemia and cardiovascular disease.
Levy P
Postgrad Med; 2009 May; 121(3 Suppl 1):7-12. PubMed ID: 19494472
[TBL] [Abstract][Full Text] [Related]
18. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy.
Chapman MJ; Sposito AC
Pharmacol Ther; 2008 Mar; 117(3):354-73. PubMed ID: 18215759
[TBL] [Abstract][Full Text] [Related]
19. [Implementation of clinical guidelines in general practice. The effect of journal audit and continuing education for the treatment of cardiovascular risk factors in patients with and without type 2 diabetes].
Madsbad S; Larsen ML; Adeler HF; Kryhlmand M; Westergaard M
Ugeskr Laeger; 2006 Apr; 168(17):1640-5. PubMed ID: 16674875
[TBL] [Abstract][Full Text] [Related]
20. Metabolic syndrome: is it a syndrome? Does it matter?
Kahn R
Circulation; 2007 Apr; 115(13):1806-10; discussion 1811. PubMed ID: 17404171
[No Abstract] [Full Text] [Related]
[Next] [New Search]
